Almost all trials for recurrent GBM patients ‘based on a high percentage of them expressing EGFR (40%–60%)’ evaluating EGFR TKIs utilised a continuous daily dosing schedule but also included unenriched participants (Table 1). Here, EGFR is linked to glioblastoma.